NASDAQ · Biotechnology

GNLX (GNLX) Stock

$2.94 -3.61% NASDAQ: GNLX Healthcare

Valuation

MetricValue
Price$2.94
Market Cap$131.83M
P/E Ratio-3.41
P/B Ratio9.18
P/S Ratio13777.19
EPS (TTM)$-0.86
52-Week High$8.54
52-Week Low$2.29
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-266.67%
ROA-168.42%
ROCE-275.00%
Gross Margin-35.50%
Operating Margin-4220.37%
Net Margin-3972.25%
Debt/Equity0.11
Current Ratio2.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$11.0M$0$0$0
Operating Profit$-15.0M$-3.0M$-24.0M$-32.0M$-33.0M
Net Profit$-18.0M$-5.0M$-28.0M$-30.0M$-32.0M
EPS$-0.69$-0.21$-1.16$-0.95$-0.86
Op Margin—-27.2%-14214.7%-396200.0%-415175.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$8.0M$6.0M$28.0M$35.0M$19.0M
Total Liabilities$41.0M$41.0M$8.0M$8.0M$7.0M
Cash$4.0M$0$9.0M$9.0M$5.0M
Borrowings$25.0M$26.0M$3.0M$2.0M$2.0M

Latest News

Attovia Therapeutics Appoints John W. Smither to Board of Directors GlobeNewswire · Jul 15, 2026 Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer GlobeNewswire · Jun 30, 2026 Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates GlobeNewswire · May 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-7.0M$-4.0M$-20.0M$-21.0M$-25.0M
Investing Cash Flow$0$0$-16.0M$-9.0M$11.0M
Financing Cash Flow$0$-1.0M$4.0M$1.0M$0
Net Cash Flow$-7.0M$-4.0M$9.0M$-1.0M$-3.0M
Free Cash Flow$-7.0M$-4.0M$-21.0M$-22.0M$-26.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-25.30%
Quick Ratio3.68
Interest Coverage—
Return 1Y-6.98%
Return 3Y-90.99%
Return 5Y—

Ownership

Insiders Held13.12%
Institutions Held30.74%
Institutions Float Held35.38%
Institutional HolderSharesReport Date
Woodward Diversified Capital, LLC2,117,1832026-03-31
Vanguard Capital Management LLC1,695,4802026-03-31
Bleichroeder LP1,380,6662026-03-31
Geode Capital Management, LLC453,7612026-03-31
Blackrock Inc.405,8722026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACIU $2.31 +0.22% -4.04 $234.59M 0.00%
ALDX $1.60 +3.23% -2.77 $96.51M 0.00%
CADL $10.59 +0.09% -11.10 $775.93M 0.00%
CLLSCellectis S.A. $2.81 -2.26% -4.14 $282.17M 0.00%
CTNM $14.16 +2.16% -6.62 $529.39M 0.00%

About GNLX

GNLX is led by CEO Thomas D. Zindrick, employs 24 people, headquartered in US, publicly traded since 2023.

GNLX stock trades at $2.94 with a market capitalization of $131.83M. The stock is valued at a price-to-earnings (P/E) ratio of -3.41, price-to-book of 9.18, price-to-sales of 13777.19. Over the past 52 weeks the stock has ranged between $2.29 and $8.54, and currently trades 65.6% below its 52-week high.

On profitability, GNLX generates a return on equity (ROE) of -266.67%, return on capital employed of -275.00%, an operating margin of -4220.37%, a net profit margin of -3972.25%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides